UNIVERCELLS
18.2.2020 13:02:08 CET | Business Wire | Press release
Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, that is focused on next-generation bioprocessing technologies for the production of advanced biologic therapies including gene- and cell-based therapies. The investment will be deployed in a newly created subsidiary of Univercells focused on accelerating the industrialization and commercialization of Univercells’ manufacturing technologies, including the NevoLine™ biomanufacturing platform and the scale-X™ bioreactor portfolio.
With the new financing, Univercells will focus on scaling the NevoLine platform and the scale-X portfolio with a comprehensive approach to streamline production, fund innovation, enable new product and application development and drive commercial acceleration. Specifically, the investment is intended to support continued expansion into the fast-growing gene therapy segment, including new developments that will enable a range of best-in-class solutions for viral manufacturing.
“KKR and Gamma will open access to an unparalleled global network, enabling accelerated production and delivery of the NevoLine and scale-X technologies and driving commercialization,” said Hugues Bultot, CEO of Univercells. “Aligning with high-end sponsors such as KKR that back our mission to have a positive impact on global health is a true honor for our team. This investment builds on existing grants from the Bill & Melinda Gates Foundation , Global Health Investment Fund and European Investment Bank and secures our ability to create value for the market with speed, efficacy and reliability.”
Both the scale-X bioreactor portfolio and the NevoLine biomanufacturing platform have been designed and commercially validated to reduce dramatically the footprint, capital and operational expenditures required to produce a variety of biologic and viral products. The investment is driven by a shared desire to make these breakthrough technologies more readily accessible and positively impact global health via effective, cost-controlled production solutions.
“KKR, through Gamma Biosciences, seeks to back innovative and impactful next-generation bioprocessing technologies, which is why we are excited to be investing in Univercells and its mission to deliver affordable biologics and gene therapies globally. Furthermore, we are excited to be working with Hugues and his team, who have a fantastic track record of building innovative biomanufacturing companies.” said Kugan Sathiyanandarajah, Director at KKR and Head of Europe for KKR’s Health Care Strategic Growth investing efforts, and Anuv Ratan, Principal at KKR.
The transaction is expected to close in the first half of 2020. Once the transaction is complete, Univercells’ remaining business will concentrate on developing a portfolio of vaccines and biosimilars to be delivered at an affordable price and establishing its services offering.
About Univercells
Univercells
is a business-to-business provider focused on increasing the availability of affordable biologics to address global health challenges. The company is developing turnkey solutions for a series of vaccines and biotherapeutics to be delivered at an affordable price. By relying on proprietary core technologies and a continuous process intensification approach, production is achieved with a smaller footprint and significantly lower overall capital and operational costs.
A global company headquartered in Gosselies (Belgium), Univercells benefits from the support of prominent stakeholders such as the Bill & Melinda Gates Foundation, the Global Health Investment Fund and the European Investment Bank.
About KKR
KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR's investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at www.kkr.com and on Twitter @KKR_Co.
About Gamma Biosciences
Gamma Biosciences is a life sciences tools platform created by KKR. Gamma’s mission is to build a leading player in next-generation bioprocessing for advanced therapies by acquiring or investing in high-potential businesses with outstanding technology and accelerating their growth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tula Technology Builds Global Momentum Expanding OEM and Tier 1 Engagements4.2.2026 08:00:00 CET | Press release
Provides 2026 business outlook with multiple start of production (SOP) targets in 2027 Tula Technology, Inc., a leader in propulsion efficiency and developer of Dynamic Motor Drive® (DMD), today provided a business update highlighting further technical progress across China and Europe as the Company advances towards global commercialization. In the fourth quarter of 2025, another Global Tier 1 completed DMD testing, achieving efficiency exceeding expectations. The Company also signed two additional memoranda of understanding, expanding engagement with OEMs and Tier 1 suppliers. In total, Tula is advancing six development programs towards a start of production (SOP) in 2027, with additional programs to follow. In China, Tula has recently signed two additional agreements – one with a Chinese OEM and another with a global Tier 1 supplier. The OEM has already begun dynamometer testing to confirm the DMD benefit, and upon meeting expectations, an over-the-air update adding DMD software into
LINVO AG Sponsors Fight Aids Cup 2026 in Monaco4.2.2026 07:00:00 CET | Press release
Football legends unite with royalty for HIV awareness at Stade Louis II When Leonardo Bonucci, Andriy Shevchenko and Clarence Seedorf lined up alongside Formula 1 star Charles Leclerc on January 24, 2026, it wasn't for a trophy - it was for a cause. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203762724/en/ LINVO AG serves as an Official Sponsor of the Fight Aids Cup Monaco 2026, uniting football legends for the global fight against HIV/AIDS. LINVO AG proudly sponsored Cirque FC at the sixth annual Fight Aids Cup, held at Monaco's iconic Stade Louis II. The charity match raised funds for Fight Aids Monaco, the HIV awareness foundation chaired by H.S.H. Princess Stéphanie. For over two decades, Fight Aids Monaco has worked to break down barriers surrounding HIV/AIDS - funding prevention programmes, supporting research, and providing direct assistance to those living with the disease. The Fight Aids Cup has become the fou
Murata’s Releases Technology Guide to Enhance Power Stability in AI-driven Data Centers4.2.2026 03:00:00 CET | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has launched a new technology guide entitled: ‘Optimizing Power Delivery Networks for AI Servers in Next-Generation Data Centers.’ Available on the company’s website, the guide introduces specific power delivery network optimization solutions for AI servers that enhance power stability and reduce power losses across the data center infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203101664/en/ [Murata Manufacturing Co., Ltd.] Technology guide to enhance power stability in AI-driven data centers The guide addresses the rapid advancement and adoption of AI, a trend driving the continuous rollout of new data centers worldwide. As the industry moves toward higher voltage operations and increased equipment density, the resulting increase in overall power consumption has made stable power delivery a critical business issue for data center operators.
The Global Photonics Community Converges in San Francisco as More Than 23,000 Register for Photonics West 20263.2.2026 22:14:00 CET | Press release
The largest annual optics and photonics event highlighted the industry’s best and brightest during a week full of innovation, networking, and research sharing SPIE, the international society for optics and photonics, brought the global optics and photonics community to San Francisco, California, for another successful and enlivening Photonics West. With more than 23,000 registrants, the annual conference and exhibition connected attendees from 40 countries, showcasing the transnational and collaborative spirit of the interdisciplinary industry. The dynamic event ran from 17 to 22 January, with 4,200 technical presentations across 100 conferences, 4 stages of industry-focused panels and presentations, 49 courses, and approximately 1,600 exhibitors in the five expos: Photonics West, BiOS, Quantum West, AR | VR | MR, plus, in its inaugural year, Vision Tech. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203925940/en/ Attend
Vena To Acquire Acterys, Creating a New Category of Enterprise Performance Management: Orchestrated Planning3.2.2026 17:00:00 CET | Press release
The acquisition unites finance foresight and IT innovation in the first Microsoft-native Orchestrated Planning environment, helping enterprises plan better and achieve more by turning strategy into aligned execution in real time. Vena, the only complete FP&A platform powered by agentic AI and purpose-built to amplify the Microsoft technology ecosystem, today announced it has entered into a definitive agreement to acquire Managility Pty Ltd, operating as Acterys (“Acterys”), the industry’s leading Power BI–based operational planning and app development platform, subject to customary closing conditions and regulatory approval. This acquisition unlocks a category-defining way for enterprises to combine planning, analytics, and application development within the Microsoft tools they already trust to run their business. By combining Vena’s Excel-native financial planning and analysis (FP&A) capabilities with Acterys’ proprietary Power BI write-back engine and unified analytics within Micros
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom